Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3963 |
Name | thyroid gland carcinoma |
Definition | A thyroid gland cancer that has_material_basis_in epithelial cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer thyroid cancer thyroid gland carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
RET C634W | Sorafenib | thyroid gland carcinoma | sensitive | detail... |
RET C634W | Ponatinib | thyroid gland carcinoma | sensitive | detail... |
RET M918T | Ponatinib | thyroid gland carcinoma | sensitive | detail... |
RET C634W | Cabozantinib | thyroid gland carcinoma | sensitive | detail... |
BRAF V600E PIK3CA H1047R | Dabrafenib + Everolimus + Trametinib | thyroid gland carcinoma | predicted - sensitive | detail... |
BRAF V600E PIK3CA H1047R | Everolimus | thyroid gland carcinoma | resistant | detail... |
BRAF V600E PIK3CA H1047R | Dabrafenib + Trametinib | thyroid gland carcinoma | resistant | detail... |
BRAF V600E | Dabrafenib | thyroid gland carcinoma | predicted - sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | thyroid gland carcinoma | predicted - sensitive | detail... |
RET M918T | Selpercatinib | thyroid gland carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01208051 | Phase Ib/II | Cediranib + Lenalidomide Cediranib | Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer | Completed | USA | CAN | 0 |
NCT01655719 | Phase II | Pioglitazone | Pioglitazone in Thyroid Cancers | Completed | USA | 0 |
NCT02428712 | Phase Ib/II | PLX8394 | A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors | Completed | USA | 0 |
NCT02628067 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Recruiting | USA | POL | NOR | NLD | ITA | ISR | FRA | ESP | DNK | DEU | BRA | AUS | 9 |
NCT02834013 | Phase 0 | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
NCT03181100 | Phase II | Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab Atezolizumab + Nab-paclitaxel Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Paclitaxel | Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT04171622 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer | Recruiting | USA | 0 |
NCT04619316 | Phase II | Dabrafenib + Trametinib Trametinib | Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition (ERRITI) | Recruiting | DEU | 0 |
NCT04759911 | Phase II | Selpercatinib | Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT05786924 | Phase I | BDTX-4933 | A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers | Active, not recruiting | USA | 0 |
NCT05852223 | Phase II | Pembrolizumab | Pembrolizumab in High-risk Thyroid Cancer (NePenThe) | Not yet recruiting | ITA | 0 |
NCT05949424 | FDA approved | Lenvatinib Olaparib Pazopanib Palbociclib Sunitinib | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults (OPTI-DOSE) | Not yet recruiting | NLD | 0 |